Abstract Cycle control and tolerability of two monophasic oral contraceptive pills containing 30 microg ethinyl estradiol (EE) with either 150 microg desogestrel (DSG) or 75 microg gestodene (GSD) were compared in women starting oral contraception. A minimum of 200 healthy women at risk for pregnancy were to be treated for a total of 6 cycles per patient in a prospective, randomized open parallel-group multicenter trial. Two hundred and forty-one subjects were randomized, 115 to DSG/EE and 126 to GSD/EE. Compliance to the study preparation was high (around 95%) in both groups and no pregnancies occurred during the study. Cycle control was excellent; there were no differences between the two groups with regard to incidence of spotting and breakthrough bleeding or duration and intensity of withdrawal bleeding. Side-effects were mild and in general comparable in the two groups. Both at baseline and during treatment, a higher proportion of women taking GSD/EE complained about breast tenderness. This resulted in more early withdrawals because of breast tenderness in the GSD/EE group. It was concluded that monophasic DSG/EE and GSD/EE are equally effective, have similar cycle control and both are generally well tolerated.
COMPARATIVE STUDY ON THE ACCEPTABILITY OF TWO MODERN MONOPHASYC ORAL CONTRACEPTIVE PREPARATIONS:30 MCG ETHYNIL ESTRADIOL COMBINED WITH 150 MCG DESOGESTREL OR 75 MCG GESTODENE / L., Zichella; C., Sbrignadello; A., Tomassini; A., DI LIETO; C., Montoneri; G., Zarbo; M., Mancone; P., Pietrobattista; G., Bertoli; Perrone, Giuseppina. - In: ADVANCES IN CONTRACEPTION. - ISSN 0267-4874. - 15(3):(1999), pp. 191-200. [10.1023/A:1006745315344]
COMPARATIVE STUDY ON THE ACCEPTABILITY OF TWO MODERN MONOPHASYC ORAL CONTRACEPTIVE PREPARATIONS:30 MCG ETHYNIL ESTRADIOL COMBINED WITH 150 MCG DESOGESTREL OR 75 MCG GESTODENE
PERRONE, Giuseppina
1999
Abstract
Abstract Cycle control and tolerability of two monophasic oral contraceptive pills containing 30 microg ethinyl estradiol (EE) with either 150 microg desogestrel (DSG) or 75 microg gestodene (GSD) were compared in women starting oral contraception. A minimum of 200 healthy women at risk for pregnancy were to be treated for a total of 6 cycles per patient in a prospective, randomized open parallel-group multicenter trial. Two hundred and forty-one subjects were randomized, 115 to DSG/EE and 126 to GSD/EE. Compliance to the study preparation was high (around 95%) in both groups and no pregnancies occurred during the study. Cycle control was excellent; there were no differences between the two groups with regard to incidence of spotting and breakthrough bleeding or duration and intensity of withdrawal bleeding. Side-effects were mild and in general comparable in the two groups. Both at baseline and during treatment, a higher proportion of women taking GSD/EE complained about breast tenderness. This resulted in more early withdrawals because of breast tenderness in the GSD/EE group. It was concluded that monophasic DSG/EE and GSD/EE are equally effective, have similar cycle control and both are generally well tolerated.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.